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Next-Generation Sequencing Panels for Detection
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Avni Santani, PhD; Jill Murrell, PhD; Birgit Funke, PhD; Zhenming Yu, PhD; Madhuri Hegde, PhD; Rong Mao, MD;
Andrea Ferreira-Gonzalez, PhD; Karl V. Voelkerding, MD; Karen E. Weck, MD
 Context.—The number of targeted next-generation se-
quencing (NGS) panels for genetic diseases offered by
clinical laboratories is rapidly increasing. Before an NGS-
based test is implemented in a clinical laboratory,
appropriate validation studies are needed to determine
the performance characteristics of the test.
Objective.—To provide examples of assay design and
validation of targeted NGS gene panels for the detection of
germline variants associated with inherited disorders.
Data Sources.—The approaches used by 2 clinical
laboratories for the development and validation of targeted
NGS gene panels are described. Important design and
validation considerations are examined.
Conclusions.—Clinical laboratories must validate per-
formance specifications of each test prior to implementa-
tion. Test design specifications and validation data are
provided, outlining important steps in validation of
targeted NGS panels by clinical diagnostic laboratories.
(Arch Pathol Lab Med. 2017;141:787–797; doi: 10.5858/
arpa.2016-0517-RA)
W ith the advent of massively parallel sequencing,commonly called next-generation sequencing (NGS),
methodologies, the number of genes implicated in human
disease has increased substantially in the last decade. The
increase in gene discovery has led to a surge in the number
of clinical laboratory tests offered to detect genetic variants
associated with inherited disorders. Many disorders, such as
sensorineural hearing loss, cardiomyopathy, and RASopa-
thies, are genetically and clinically heterogeneous with
variants in numerous genes resulting in the overlapping
phenotypes. In contrast to a sequential (gene-by-gene)
testing approach, such as Sanger sequencing, a disease-
targeted NGS panel focused on the simultaneous analysis of
a set of genes associated with a specific clinical indication is
often a suitable cost-effective alternative. A laboratory must
take gene- and disease-specific parameters into consider-
ation when designing and analytically validating NGS-
based gene panels for clinical testing. General guidelines for
clinical NGS assays have been published by the American
College of Medical Genetics and Genomics, the College of
American Pathologists, the National Committee for Clinical
Laboratory Standards, and the Association for Molecular
Pathology.1–3 The College of American Pathologists Bio-
chemical and Molecular Genetics Committee has previously
published examples of assay validation for molecular genetic
testing, including a methods-based approach for validation
of laboratory-developed testing by Sanger sequencing and
verification of a US Food and Drug Administration–
approved assay for cystic fibrosis mutation testing.4,5 In this
manuscript, we describe examples of the design and
validation of NGS targeted panels for inherited disorders.
Key considerations for test design, assessment of the validity
of gene-disease relationships, validation criteria, and quality
measures are addressed. Specifically, a methods-based
validation approach6 that was implemented at the Child-
ren’s Hospital of Philadelphia, Philadelphia, Pennsylvania,
is described. We report an integrated validation strategy
using HapMap samples and samples with specific disease
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variants for a combined targeted NGS panel for 5 diseases,
including early infantile epileptic encephalopathy, craniofa-
cial disorders, RASopathy disorders, hearing loss, and
hereditary cancer. Additional test design considerations
are highlighted using examples from the Laboratory for
Molecular Medicine at Partners HealthCare Personalized
Medicine, Boston, Massachusetts.
FAMILIARIZATION AND PLANNING
Disorders with significant locus and allelic heterogeneity,
that is, those caused by multiple different sequence
variants in one of several different genes, are typically
prioritized for panel testing. Key considerations including
specimen volume, expected turnaround time, and calcula-
tions of labor, time, and cost of reagents to perform and
analyze the test can inform decision making about clinical
test development. As with other molecular genetic tests,
NGS germline panels can have several useful applications,
such as confirming a clinical or prenatal diagnosis,
facilitating presymptomatic surveillance, and developing
strategies for management and early intervention. It is
important to select genes with sufficient scientific evidence
of a causative role in the disease, as variants in genes that
are not yet established as disease causing are difficult to
interpret and can lead to inconclusive results. Determina-
tion of the clinical validity of genes and corresponding
variants often relies on the evidence presented in published
literature. However, the type and depth of published
evidence vary greatly for different genes, and objectively
assessing the clinical validity of the disease association of
genes can therefore be challenging. Thus, it is important
for clinical laboratories to establish an objective method to
curate and classify the evidence used to determine the
strength of gene-disease associations. At the present time
there are no expert or regulatory guidelines as to what level
of evidence warrants inclusion of a gene in a test designed
for diagnosis of a specific inherited disorder, and as a
consequence, test content can vary substantially across
testing laboratories. A comprehensive evidence-based
framework for evaluating gene-disease association validity
has been recently made available by the Clinical Genome
Resource or ClinGen (https://www.clinicalgenome.org/
knowledge-curation/gene-curation/).
Once the gene content for a targeted NGS panel is
determined, the next step is to determine the genomic
region of interest. Many genes have multiple, alternatively
spliced transcripts whose spatiotemporal expression can
vary. Currently, there is no consensus among laboratories or
specifications by regulators in selection of which transcript
should be used for sequencing analysis and annotation.
Existing approaches range from using a single transcript (eg,
the one with the most exons or the one that is
predominantly expressed in the tissue of interest) to a more
inclusive ‘‘all-exon’’ approach. The constraint to the latter
approach is that the relative importance of individual
transcripts is often not well defined. Because multiple
transcripts may be defined for a particular gene, it is
important to include the transcript used for variant reporting
in the laboratory report by referencing the messenger RNA
transcript and protein sequence numbers for complemen-
tary DNA and protein nomenclature respectively. Once the
transcripts for each gene have been selected, coding exons
with flanking intronic regions are used to define the region
of interest. There is currently no consensus on the length of
intronic sequence that should be included in analysis,
although most laboratories include sequences from 610 to
20 bases past the intron-exon boundary in order to detect
intronic mutations in the splice donor and acceptor
sequences. However, it may be important to include more
deep intronic regions, for example if known pathogenic
mutations occur within an intron in a specific gene.
A thorough review of the variant spectrum associated
with each gene is essential to identify common pathogenic
variants or hot spots and pathogenic variants located
outside of typically covered exonic regions, such as deep
intronic or untranslated regions. This information is
essential to determine the targeted genomic region of
interest and can be valuable when selecting validation
specimens. It is also important for determining the clinical
sensitivity of testing, that is, what percentage of patients
with disease will have a mutation that is detectable by the
targeted region. For example, CFTR-related disorders are
caused by single-nucleotide variants (SNVs) in exons, 50 and
30 untranslated regions, deletions, insertions/duplications,
complex rearrangements, and intronic repeat variations.
Another example is a common pathogenic variant in the
Fabry disease gene (GLA) that would be missed if a standard
exon-targeted design is applied. The deep intronic c.640-
801G.A variant in GLA is a frequent cause of the X-linked
cardiac type of Fabry in the Taiwan Chinese population.7
Information about the disease, including key clinical
indicators, disease mechanism, prevalence, mode of inher-
itance, penetrance, and expressivity, should be investigated
at the test design stage. All of these factors play a critical role
when interpreting results and writing a clear, concise report.
Example
For the methods-based validation approach described
below (see Analytical Sensitivity, Specificity, and Precision
section), 151 genes associated with 5 diseases were
combined in one panel (12 genes for RASopathy, 97 for
hearing loss, 17 for craniofacial disorders, 11 for hereditary
cancer, and 15 for early infantile epileptic encephalopathy;
Supplemental Table 1, contained in the supplemental digital
content [containing 5 tables and 1 figure]) is available at
www.archivesofpathology.org in the June 2017 table of
contents. One gene, MSX2, was present in both the
craniofacial and hearing loss syndromes. Genes and
diseases were reviewed and scored for clinical validity.
Information about the disease mechanism, mode of
inheritance, and transcripts was noted in a central database
(data not shown here). All coding exons (610 base pairs
[bp] into the intron) were targeted for each gene. In total a
~0.5-Mb region was targeted for panel design and
development.
Using the general guidelines listed above, the following is
an example of gene curation for FGFR3 in designing a
targeted NGS panel for a craniosynostosis panel. Variants in
FGFR3 have been observed in 100% of individuals with
Crouzon syndrome with acanthosis nigricans and in 100%
of individuals diagnosed with Muenke syndrome.8 FGFR3
has 3 transcripts and 18 coding exons. In severe presenta-
tions, de novo pathogenic variants in affected individuals are
observed. Advanced paternal age has been reported to be
associated with de novo pathogenic variants in Muenke
syndrome.9 The majority of pathogenic variants in FGFR3
are missense changes that result in an autosomal dominant
gain of function effect. There is one recurring pathogenic
variant, c.749C.G; p.Pro250Arg, that is the single cause of
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Muenke syndrome.10 Based on this information, the
targeted capture panel was designed to include genomic
regions that encompass the coding region. Validation
experiments were designed to include a positive control to
confirm that the c.749C.G; p.Pro250Arg variant could be
detected using the laboratory-based approach (Table 1).
TECHNICAL CONSIDERATIONS
During the design of an NGS gene panel, is it important
for the laboratory to be aware of technical limitations of
NGS technology. Many of these limitations may be inherent
to all technologies, but some are specific to particular
enrichment, sequencing, or bioinformatics techniques.
Technical Limitations
Interference of Homologous Sequences.—There are
significant challenges in interrogating medically significant
genes with high sequence homology. Some genes, or parts
of genes, may not be adequately captured or sequenced to
allow for confidence in quality of the data. These include
genes with complex sequence contexts such as pseudo-
genes, genetic rearrangements, and a high GC content.
Regions of high homology with other genomic regions, such
as pseudogenes or gene duplication events, may lead to
false-positive and/or false-negative results due to mismap-
ped reads. It is critical that laboratories assess regions of
homology to identify genomic regions within the targeted
gene panel that may not be uniquely present in the genome.
Variant calls in highly homologous regions that cannot be
accurately detected by NGS can often be resolved by other
methods such as Sanger sequencing if gene-specific primers
can be designed. If that is not possible, affected regions may
need to be excluded from the panel. If the excluded gene or
region is critical to diagnosis of the disease, other methods
such as long-range polymerase chain reaction may need to
be used. Regions that are difficult to interrogate by NGS,
such as those with high or low GC content and homologous
regions, are particularly important to assess during the assay
validation, especially in a methods-based validation ap-
proach. Short read lengths can make sequence assembly
and alignment challenging when homology to other loci is
present. Target sequences therefore need to be carefully
examined to determine if the sequence context is amenable
to short-read NGS. If significant challenges are evident,
non-NGS assays may need to be added to the test to ensure
optimal clinical validity.11
Exon Level Deletions and Duplications.—Deletion or
duplication at exon level can be detected via NGS using
several commercially available bioinformatics tools; howev-
er, the analytical sensitivity and specificity of these changes
must be determined by the laboratory.12
Repeat Regions.—Clinically significant homopolymer
tracts and triplet repeat expansions are usually not able to
be detected by standard NGS and are better analyzed using
other methods.
Other Limitations.—Mosaicism and low levels of heter-
oplasmy for mitochondrial DNA variants may not be
detected, depending on the depth of sequence coverage
and limit of detection that is validated. Depending on the
availability of parental DNA, the chromosomal phase of
Table 1. Samples With Previously Identified Heterozygous Variants That Were Used for Validation
of the Combined Disease Panels
Gene Transcript Variant Type Chr Pos (GRCH37) Panel
CDKL5 NM_001037343.1 c.2384A.C, SNV ChrX:18643255 Epileptic encephalopathy
p.Asn795Thr
CDKL5 NM_001037343.1 c.380A.G, SNV ChrX:18598065 Epileptic encephalopathy
p.His127Arg
FGFR1 NM_023110.2 c.755C.G, SNV Chr8:38282208 Craniofacial
p.Pro252Arg
FGFR2 NM_000141.4 c.1018T.C, SNV Chr10:123276899 Craniofacial
p.Tyr340His
FGFR3 NM_001163213.1 c.749C.G, SNV Chr4:1803571 Craniofacial
p.Pro250Arg
FLCN NM_144997.5 c.1285delC, Indel Chr17:17119709 Hereditary cancer
p.His429ThrfsX39
FLCN NM_144997.5 c.1285dupC, Indel Chr17:17119709 Hereditary cancer
p.His429ProfsX27
GJB2 NM_004004.5 c.35delG, Indel Chr13:20763686 Hearing loss
p.Gly12ValfsX2
MAP2K1 NM_002755.3 c.388T.C, SNV Chr15:66729180 RASopathy
p.Tyr130His
MYO7A NM_000260.3 c.3719G.A, SNV Chr11:76901153 Hearing loss
p. R1240Q
MYO7A NM_000260.3 c. 1344-2A.G SNV Chr11:76873164 Hearing loss
PCDH15 NM_033056.3 c.4024C.A, SNV Chr10:55591253 Hearing loss
p.Gln1342Lys
SLC26A4 NM_000441.1 c.565G.T, SNV Chr7:107314758 Hearing loss
p.Ala189Ser
SOS1 NM_005633.3 c.1654A.G, SNV Chr2:39249915 RASopathy
p.Arg552Gly
TWIST1 NM_000474.3 c.396dupG, Indel Chr7:19156549 Craniofacial
p.Lys133GlufsX105
USH1C NM_153676.3 c.1069C.T, SNV Chr11:17542909 Hearing loss
p.Arg357Trp
VHL NM_000551.3 c.402delA, Indel Chr3:10188259 Hereditary cancer
p.Glu134AspfsX25
Abbreviations: Chr Pos, chromosome position; indel, insertion/deletion; SNV, single-nucleotide variant.
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identified pathogenic variants may not be determined (ie,
whether variants are in cis or trans). Rare variants in primer
or probe hybridization sites may compromise analytical
sensitivity. Because a multigene panel is typically focused on
the coding regions of the gene, regulatory region and deep
intronic variants may not be identified.
Based on the design and validation data, a laboratory may
decide whether to use another method to fill in for genomic
regions that cannot be accurately analyzed by NGS or to
exclude the region from analysis. Genomic regions that are
not covered by testing should be included in the assay
description and laboratory report and clinical sensitivity
calculations should be adjusted accordingly.
Example
Below we provide an example from the Laboratory for
Molecular Medicine during the development of a hearing
loss panel, which lists genes with high homology and/or
high GC content (see Supplemental Table 2 for complete
gene list). Table 2 shows (1) the number of exons that are
affected by high homology to other loci (here defined as
90% of all bases with a mappability score11 of ,1) and (2)
the number of exons with unusually high (.75%) or low
(,35%) GC content. The STRC gene illustrates a gene that
cannot be analyzed with standard short-read NGS methods
(28 of 29 exons have high homology with a pseudogene,
with long stretches being 100% identical across exons and
introns between the 2 genes13). Because this gene is a key
contributor to nonsyndromic hearing loss14 and clinical
specificity (the ability to deduce the genetic cause based on
the patient’s clinical features) is low, it was deemed critical
to be included in a diagnostic gene panel for inherited
hearing loss, and this can be accomplished by supplement-
ing the NGS assay with a long-range polymerase chain
reaction assay that discriminates between the gene and its
pseudogene.13 The TMC1 gene is also affected by homology
and GC issues; however, in this case homology is restricted
to 1 exon and 4 exons have low GC content. Based on
whether these exons are critical, the laboratory director may
decide to drop them from the test, particularly if unique
Sanger sequencing primers cannot be designed for confir-
matory purposes. In this case, unique Sanger sequencing
primers were available for the TMC1 exon with homology to
another genomic region. Much of the OTOGL gene (34 of 58
exons) has low GC content. Although this may result in
poor coverage/data quality, it was considered worth
generating validation data first to gauge the true extent of
this problem. If the number of exons that fail NGS analysis
is low, Sanger sequencing may be used to fill in
insufficiently covered regions.
For genomic regions that are difficult to analyze by NGS,
it may be advisable to investigate the feasibility of
developing robust Sanger sequencing primers in parallel,
for example to explore whether primer design is possible
in these regions. The development of companion Sanger
sequencing assays can be approached in different ways
depending on the laboratory’s general operational ap-
proach. For small gene panels, it is often possible and
efficient to predevelop orthogonal assays for all exons
covered by the test. This strategy does not scale with
increasing gene content, as many assays will never be
needed (either because no variant is ever detected that
needs confirmation and/or the region performs robustly by
NGS and do not need confirmation by Sanger sequenc-
ing). It may be more practical to restrict Sanger predevel-
opment to vulnerable regions that have an increased
likelihood to fail. A pilot run will identify problem regions
(ie, those that always fail), but the scope of most test
development efforts is usually insufficient to allow
identifying all genomic regions of reduced robustness. It
is for those regions that an upfront in silico ascertainment
of the targeted test region is most useful. Figure 1
summarizes key concepts and provides a decision matrix
for dealing with genomic regions that are difficult to
sequence by NGS technology.
Selection of Target Enrichment and Sequencing Techniques
A critical step in test development is choosing which
sequencing technology and enrichment techniques to use.
Several commercial NGS platforms are available. Each
sequencing platform has specific parameters that differ in
sequence capacity, sequence read length, sequence run
time, and quality and accuracy of the data. Size of the
targeted region, type of variation detected, required depth of
Table 2. Analysis of Hearing Loss Panel Genes for GC Content and Regions of Homology
Gene No. of Exons
No. of
Exons With
Homology Issue
No. of Exons
,35% GC
No. of Exons
.75% GC Notes
STRC 29 28 0 0 Alert: special assay because of high homology (long
stretches are 100% identical)
TMC1 20 1 4 0 Alert: check if exon can be covered by Sanger (can
unique primers be designed). If not, can it be
dropped?
CISD2 3 1 1 0
OTOGL 58 0 34 0 Watch list: low GC—can be problematic
MYO6 34 0 27 0 Watch list: low GC—can be problematic
GPR98 90 0 24 0 Watch list: low GC—can be problematic
MYO3A 33 0 18 0 Watch list: low GC—can be problematic
HSD17B4 26 0 13 0 Watch list: low GC—can be problematic
PCDH15 39 0 12 0 Watch list: low GC—can be problematic
RDX 14 0 10 0 Watch list: low GC—can be problematic
SERPINB6 9 0 1 1 Watch list: high GC—can be problematic
GIPC3 6 0 0 1 Watch list: high GC—can be problematic
KCNQ1 17 0 0 1 Watch list: high GC—can be problematic
P2RX2 10 0 0 1 Watch list: high GC—can be problematic
TMIE 4 0 0 1 Watch list: high GC—can be problematic
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coverage, projected sample volume, turnaround time
requirements, and costs are all considered when choosing
a sequencer. For a comprehensive review on NGS
technologies, the reader is referred to Mardis15 and
Metzker.16
All NGS targeted panels require enrichment of targeted
genomic regions prior to sequencing. There are several
strategies in which target enrichment can be achieved.
These methods include polymerase chain reaction–based
capture, molecular inversion probe–based capture, and
hybrid capture methods. Each approach varies in sensitivity
(percentage of target bases that are represented by one or
more sequence reads), specificity (percentage of sequences
that map to the intended targets), uniformity (variability in
sequence coverage across target regions), reproducibility
(correlation of results obtained from replicate experiments),
cost, ease of use, and amount of DNA required. Mamanova
et al17 provides a comprehensive review of target-enrich-
ment strategies. The data shown here were generated with a
targeted hybridization-based approach using SureSelect for
target enrichment (Agilent Technologies, Santa Clara,
California) and sequenced using the MiSeq system (Illumi-
na, Inc, San Diego, California).
Bait Design Strategy
Vendors of target capture assays typically allow custom
design of baits. One key consideration is bait density, as this
will impact capture efficiency (especially in difficult regions).
To ensure reliable capture, it is advantageous to choose a
baiting strategy that covers each base more than once.
However, for very large targets this may not be practical for
economic reasons. If complete coverage is critical (which is
typically the case for diagnostic NGS testing) an iterative
design process may be an option, where a less dense bait
tiling is tested first and underperforming regions are then
optimized.
A second key consideration is the total bait territory. For
certain hybridization-based enrichment techniques, off-
Figure 1. Decision matrix for dealing with homologous sequences. A sample process for evaluating the test contents for homology including
possible approaches for dealing with homology is shown. Key decision nodes depend on whether or not alternate assays (such as unique Sanger
sequencing assays that discriminate against pseudogenes) need to be developed to ensure maximum clinical utility of the test. *Mappability
calculated using 250-bp stretches at 98% homology.11 Abbreviations: NGS, next-generation sequencing; PCR, polymerase chain reaction.
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target capture is expected. For regions that capture well, it
may not be necessary to cover the entire targeted region
with baits, as captured fragments typically extend beyond
both ends of a given bait. However, coverage at the edges of
the targeted region will always be significantly lower, and
these bases often are insufficiently covered. If complete
coverage above the minimal acceptable number of reads is
desired, it can therefore be beneficial to extend the baited
region beyond the actual region of interest. Figure 2 shows
the impact of these baiting strategies on final coverage for a
representative exon.
BIOINFORMATICS PIPELINE FOR ALIGNMENT,
VARIANT CALLING, ANNOTATION, AND FILTRATION
Next-generation sequencing produces an extensive
amount of sequence data that is typically processed and
analyzed in 3 major steps. The primary step, executed by
onboard instrument software, translates sequencing signals
into linear sequence with associated individual nucleotide
base quality scores analogous to Phred scores. This
information is compiled into a file format termed .fastq,
which is the input for the secondary step during which
sequence reads are aligned to a reference sequence. Aligned
reads are compiled into a file format termed .bam. Key
information in the .bam file includes read alignment
location relative to the reference, read mapping quality,
depth of read coverage per mapped location, and forward
and reverse read distribution when bidirectional sequencing
has been performed. The .bam files can be viewed in
genome browsers that also allow visualization of variants in
reads relative to the reference. The tertiary step uses the
.bam file as input into software that determines differences
between the aligned reads and the reference sequence and
compiles those differences into a variant call file format.18
The tertiary step also includes annotation of the variants (eg,
assignment of c. and p. nomenclature) and association of
variants with metadata (eg, variant frequency in popula-
tions). Each step is complex and to accomplish them
requires a combination of algorithms and software that
may be open source or commercial. The choices of
algorithms and software are influenced by sequencing
chemistry and instrumentation, the application and types
of variants to be detected (eg, SNVs or copy number
variants), and the bioinformatics expertise of the laboratory.
Critically, it has been shown that different bioinformatics
pipelines generate differences in variant outputs and
accuracy.19–21 The imperfect and evolving state of NGS
bioinformatics poses challenges for clinical laboratories with
regard to choice and evaluation of bioinformatics tools.
Further discussion on NGS bioinformatics principles can be
found in O’Rawe et al,19 Reumers et al,20 and Ross et al.21
Figure 2. Impact of baiting strategy on coverage at the end of target regions. Baiting deeper into the intronic regions (coding DNA Sequence [CDS]
þ 5 bp versus CDS 50 bp) improved coverage at the end positions of the variant reporting region.
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Once the bioinformatics pipeline has been optimized, a
comprehensive validation is performed using sequence
reads generated from samples with known variants covering
the spectrum of the diagnostic test. As described above, a
sufficient number of samples should be analyzed to assess
the pipeline’s analytic and diagnostic sensitivity and
specificity as well as precision. Once a pipeline has been
validated, any changes to the protocol need to be
documented and revalidated.
Example
For the validation data shown below (see Analytical
Sensitivity, Specificity, and Precision), a methods-based
validation was performed that encompassed the bioinfor-
matic elements. Read alignment and variant calling were
performed with an in-house bioinformatics pipeline that
incorporated NovoAlign (Novocraft, Selangor, Malaysia) for
read alignment and Picard (for duplicate removal) and the
Genome Analysis Toolkit (Broad Institute, Cambridge,
Massachusetts) for downstream processing and variant
calling (reference sequence: hg19v37). Variant annotation
and initial variant filtration were performed with Bench Lab
NGS software (Cartagenia, Cambridge, Massachusetts) for
variants with coverage of 53 or more. This filtration restricts
the data to variants in the Human Genome Mutation
Database and/or rare variants with a coding effect such as
nonsynonymous, stop loss, stop gain, start loss, insertions/
deletions (indels), frameshifts, and variants within the
consensus splice site (6 bases in the intron and 2 bases in
the exon). Additional information about the alignment and
variant calling pipeline is available in Supplemental Figure 1.
All algorithms, software, customizations, and databases
used in the analysis of NGS data were documented and
versioned. Quality control parameters were developed and
documented. Parameters and thresholds that determine the
overall quality of a successful sequencing run were
established (see Quality Assurance and Quality Control
and Supplemental Table 3).
ANALYTICAL VALIDATION
Analytical Sensitivity, Specificity, and Precision
Once the methodology is established and the protocol is
optimized in the laboratory, the entire test should be
validated, including all steps in the process (wet bench as
well as the bioinformatics analyses) using all sample types
that will be accepted for the panel (eg, whole blood; saliva;
formalin-fixed, paraffin-embedded tissue; buccal swab;
cultured amniocytes and chorionic villi). Regulatory require-
ments and quality management system standards require
that laboratories determine assay performance characteris-
tics including analytical sensitivity and specificity and
precision or reproducibility.5,22,23 All 3 of these measures
are determined by testing samples that are from individuals
with known sequence variants and known negative
controls. For validation of an NGS panel, it is not feasible
to identify and analyze controls for every possible mutation
within the targeted genes; therefore, a methods-based
validation approach was taken. The methods-based valida-
tion approach incorporates samples with known mutations,
particularly targeted to common mutations and specific
types of variants or genomic regions that may be more
difficult to detect, such as indels, GC-rich regions, and
regions of repetitive sequence. Positive control samples that
have high-confidence SNV and indel calls by whole-
genome sequencing, such as NA12878, are available
through the Coriell Institute for Medical Research, Camden,
New Jersey, and the National Institute of Standards and
Technology, Gaithersburg, Maryland. These data were
generated by the Genome in a Bottle Consortium by
integrating and arbitrating among 14 data sets.24,25 Positive
controls may also be obtained through clinical and/or
research laboratories by using previously tested methods
such as NGS or Sanger sequencing or SNP arrays.
Analytical sensitivity is the likelihood that the assay will
detect a sequence variant when present within the targeted
region (1  false-negative rate). This is determined by
dividing the number of known variants (true positives)
detected by the NGS targeted panel by the total number of
known variants detected by a reference method or data set.
It is recommended that recurrent disease-causing variants
be included in the analyses because these may be seen
frequently in a disease cohort.6
Analytical specificity is the likelihood that the assay will be
negative when no variant is present (1 false-positive rate).
This measurement is established by dividing the number of
true negatives (known reference alleles) by the sum of true
negatives and false positives, typically obtained by compar-
ison with the results obtained by a reference method such as
Sanger sequencing (or the National Institute of Standards
and Technology’s high-confidence sequence generated for
NA12878).
Knowing that current sequencing platforms and bio-
informatic pipelines exhibit differences in their capacity to
detect different classes of genetic variations, it is recom-
mended that analytical sensitivity and specificity be estab-
lished separately for each type of sequence variation such as
SNVs, indels, and copy number variants, if applicable.
Example
For the methods-based validation study conducted at the
Children’s Hospital of Philadelphia, 30 samples were used.
Among these, 15 samples were previously characterized to
carry pathogenic mutations in various target genes across
the 5 disease groups (Table 1). The remaining 15 samples
were negative controls, which included 13 DNA specimens
that tested negative for mutations in selected genes and 2
HapMap samples (NA12878 and NA19240). Genomic DNA
was extracted from blood or other patient tissues following
standard DNA extraction protocols in the laboratory.
Coding regions with 10-bp flanking intronic sequences of
genes of interest were enriched using the SureSelectXT
Target Enrichment System (Agilent Technologies) for
Illumina Paired-End Sequencing Library. Differentially
indexed postcapture libraries were sequenced using the
Miseq 23 150-bp V2 Regent Kit (Illumina).
In order to determine sensitivity and specificity of this
assay, additional data sets were obtained for select patient
samples that had been analyzed previously by alternative
technologies. Single-nucleotide variant array data were
obtained for 10 of the samples from either the Children’s
Hospital of Philadelphia cytogenomics laboratory or public
databases (such as the 1000 Genomes and EVS database). In
addition, whole-genome sequencing data for the 2 HapMap
samples were obtained from the Broad Institute and
Illumina, respectively, and the consolidated SNV data by
the Genome in a Bottle Consortium24 for one of the
HapMap samples (NA12878). For 5 patients, variant
information was available on the Noonan panel of genes
through a previously validated NGS protocol. Detailed
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information for samples used in this validation study and
corresponding reference data sets are listed in Table 1.
Analytical sensitivity and specificity of the assay were
calculated by comparing variants identified in this assay
with variants identified in the reference data sets. For
samples with SNV array results available, every position
with an array call was analyzed for concordance with the
result obtained through the NGS assay (ie, the MiSeq
result). Discordant variants were further resolved using
Sanger sequencing analysis. Results of sensitivity and
specificity studies are shown in Table 3 and Supplemental
Tables 4 and 5.
Recurring false-positive variants in HRAS and MAP2K2
were identified (Supplemental Table 4). Both of these
variants were flagged to have poor quality scores and would
have been flagged by the laboratory for confirmation by
Sanger dideoxy sequencing analysis. Repeating the assay
with the same specimen with a new enrichment kit led to
elimination of the 2 false-positive variants. It is unclear
whether it was the enrichment kit or a sample preparation
error in the original assay that led to the resolution of the
discordant variants. Based on these results, it is recom-
mended that laboratories leverage validation studies to
understand the sources of false negatives and false positives
and develop strategies to address them. For example,
laboratories may choose to review the quality and alignment
of the data using tools such as the Integrative Genomics
Viewer.26 It is recommended that laboratories develop
quality metrics for acceptability of variant calls and a policy
on when to confirm variants by an orthogonal method such
as Sanger sequencing. Based on our experience with this
validation and other additional data not shown here, we
have set the following parameters for confirmation of
variants by Sanger sequencing: (1) any variant with a read
depth less than 20, (2) call quality less than 500 (Phred score
of confidence P value), (3) genotype quality less than 99, (4)
strand bias greater than 80% of variant reads align to single
strand or (5) an allele frequency less than 40% for
heterozygous variants or less than 95% for homozygous
variants, and (6) any reportable disease causing variant
(classified as variant of uncertain significance, likely
pathogenic or pathogenic; Table 4). To be noted, these
parameters are not meant for universal use because these
are specific and unique to the sequencing and bioinfor-
matics pipeline being used in a laboratory and are likely to
undergo modifications as chemistries and informatics tools
get updated. It is recommended that every laboratory
determine these parameters based on their experience with
their internal laboratory protocols.
Two HapMap samples were also used during the validation
study. For NA12878, variants within the targeted regions
were compared with a reference variant list. Discrepancy
among the reference data sets was resolved by further
examining the GATK filter and quality score for the Broad
WGS data set, variant context, and the filter information in
the GIAB variant list. For this study, true negatives were
defined as positions without variants in the comparison
reference sample. True positives were defined as positions
with heterozygous or homozygous variant calls in the
comparison reference sample. Comparison between the
reference data set and the NGS panel data showed 1 false-
positive SNV call and 1 false-positive indel in the panel data
set. The false-positive SNV call showed very strong strand
bias in the .bam file and the indel call was identified within a
homopolymer region (.20 A), indicating that both variants
were unlikely to be true positives. In summary, for NA12878,
more than 469 121 positions within the targeted region were
correctly called as true negatives and 264 variants were called
correctly as true positives. For HapMap sample NA19240, the
WGS variant data from Illumina and the 1000 Genomes
Omin2.5 array data set were obtained and used as the
reference data sets. Comparison between the reference data
set and the variant set from the panel indicated that 469 047
positions were correctly called as true negatives and 339
variants were called correctly as true positives.
For samples with only one or a few genes previously
tested in this laboratory, variant information was extracted
from this NGS assay for genes previously tested and
compared with the previous test result (Table 1). All SNVs
and small indels (,5 bp) that are sufficiently covered (ie,
with .303 minimum per base coverage) were successfully
identified. Known pathogenic variants were compared and
the results are shown in Table 1. A mutation in the ARX
gene was not identified in the positive control because of
low coverage (,303). Exon 2 of ARX gene is GC rich and is
traditionally a region that is difficult to sequence. Greater
coverage increases the probability of correctly calling a
variant; however, there are platform-specific upper limits to
coverage. In targeted regions with low coverage, Sanger
sequencing or another method may need to be incorporated
in order to maximize sensitivity. In this study, all low
coverage exons were sequenced with complementary
Sanger sequencing; therefore, this variant was correctly
identified.
In summary, analytical sensitivity and specificity for this
method were more than 99% for SNV detection. For indel
variants, detection sensitivity and specificity were more than
99% for small indels (,5 bp) and variants within non-
homopolymer regions (,7 of the same nucleotide in a row).
Precision refers to the reproducibility or ‘‘robustness’’ of
the assay, meaning the ability to obtain the same results
from the same sample when the assay is performed
repeatedly. For reproducibility, both intrarun and interrun
reproducibility should be assessed. To evaluate intrarun
precision (repeatability), 3 libraries were prepared from the
HapMap DNA sample NA12878 in parallel, each with a
unique index. An equimolar amount of each library was
pooled and sequenced on the same Miseq flow cell. To
evaluate interrun precision (reproducibility), the HapMap
NA127878 DNA was captured and sequenced in another
independent run. Variants called for each sample/run were
compared among the 3 intrarun library samples (NA12878I,
Table 3. Summary of Analytical Sensitivity and
Specificity
Performance Measure
MiSeq Platform
% (No./Total) 95% CI
Analytical sensitivity (all
variants)
100 (1600/1600) 0.99–1.0
Analytical specificity (all
variants)
100 (1 986 875/
1 986 875)
0.99–1.0
Analytical sensitivity
(substitutions)
100 (1582/1582) 0.99–1.0
Analytical specificity
(substitutions)
100 (1 048 132/
1 048 132)
0.99–1.0
Analytical sensitivity
(insertions/deletions)
100 (18/18) 0.78–1.0
Analytical specificity
(insertions/deletions)
100 (938 743/
938 743)
0.99–1.0
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NA12878II, and NA12878III) for assessing intrarun repeat-
ability and between the interrun library sample (NA12878)
and each of the 3 intrarun samples for assessing interrun
reproducibility. Reproducibility was calculated by dividing
number of discordant calls by total positions in the region of
interest; results are shown in Table 5.
Reference and Reportable Range
Reference range is defined as the range of test values
expected for a designated population of individuals (US CFR
493; February 28, 1992). The range is determined by testing
a series of specimens from a given population who are
known to be free of the disease of concern.23 In the example,
reference range is defined as the normal variation of
sequence within the population that the assay is designed
to detect. Variation in normal individuals can include single-
base changes, insertions, deletions, and copy number
variation. Reportable range is defined as the portion of the
genome for which sequence information can be reliably
derived for a defined test system. There may be areas of the
targeted regions that cannot be sequenced reliably and thus
would be excluded from the reportable range. For example,
the targeted panel assay validated here is designed to detect
only germline mutations and is not validated for detection of
somatic mutations. Based on the validation results and the
technical limitations of NGS, variants in homopolymer
regions, indels more than 5 bp in size, genes with high
homology to pseudogenes or within repetitive regions, and
exon level copy number variation were determined to be
beyond the reportable range of this assay and thus were
excluded for calculation of sensitivity and specificity.
Mutations within the promoter regions, deep intronic
regions, or regulatory elements are outside of the targeted
regions of this assay and thus would not be detected.
VARIANT INTERPRETATION
Genomic data have revealed the complexity of the human
genome, and the concept of 1 gene–1 disease has changed.
Table 4. Quality Control (QC) Metrics Monitored for a Targeted Panel
Criteria
Metrics Measured per Sample and
Annually for Continuous Quality
Improvement
Preanalytic QC
Rejected samples Wrong sample, type of tube, insufficient quantity,
clotted, mislabeled
% of specimens rejected
DNA extraction Optical density 260/280 between 1.6 and 2.2 % of specimens with DNA extraction
failuresOptical density 260/230 between 1.6 and 3.0
Analytic QC
Library preparation QC Fragmentation size, precapture library size and
concentration, final library preparation size and
concentration, sample pooling
% of specimens with library
preparation failures
Sequencing QC Cluster density: 1350 k/mm2 % of specimens with sequencing run
failuresBase quality: % of bases with Q  30 should be
.80
Bioinformatics QC Total reads: .4M % of specimens with bioinformatics
failures% Reads aligned: .90
Average target coverage: .3003
% Region of interest: % of bases  303 depth
should be .95
Confirmation using
alternative techniques
Sanger confirmation of all reported single-nucleotide
variants and insertions/deletions. Variants flagged for
low quality:
No. of variants that failed confirmation
Call quality ,500
Genotype quality ,99
Read depth ,20
Strand ratio .80% of variant reads align to
single strand
Heterozygous allele ratio ,40% for variant
(.60% for reference)
Homozygous allele ratio ,95% for variant
(.5% for reference)
Postanalytic QC
Average turnaround time 6–8 weeks No. of specimens during stated
turnaround time
Number of positive and
negative cases
Variable across disease Monitor trends annually
Amended or corrected reports Variable Monitor annually
Table 5. Intrarun and Interrun Reproducibilitya
Intrarun or
Interrun Sample Pairing
Discordant
Variantsb
Intrarun NA12878I-NA12878II 14
NA12878II-NA12878III 14
NA12878I-NA12878III 12
Interrun NA12878-NA12878I 9
NA12878-NA12878II 11
NA12878-NA12878III 9
a For all pairings, total variants¼469 121 and reproducibility¼99.99%
(95% CI, 0.99–1.0).
b Discordant variants were identified as poor quality because of low
coverage or strand bias.
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This has implications in all areas of medicine and is not
limited to rare diseases.27 Variant interpretation is typically
performed using data from population frequency databases,
segregation analysis, mutation databases, reported studies,
and putative impact on protein function.
It is recommended that variants be interpreted using the
recently published variant classification guidelines.28,29
Those variants that occur at a high frequency (usually
greater than 5%) in a population are often filtered out by
bioinformatic analysis.29 However, for many rare disorders
or for particular genes a frequency of 5% may be too high;
thus, more stringent thresholds may be used for filtering if
information on prevalence and penetrance is available. For
reporting a variant, it is important to determine if the effect
of the variant is consistent with the patient’s phenotype and
also to examine the segregation of the variant within the
proband’s family (when family members are available).
The American College of Medical Genetics and Ge-
nomics first published recommendations for sequence
interpretation in 2005, and then again in 2008, with the
most recent revision coming in 2015, introducing the 5-
term classification system.28–30 These guidelines are
specifically directed toward inherited disease testing in
clinical laboratories, though they have also been used for
somatic variant classification. For population frequencies,
data from large-scale sequencing projects, such as the
1000 Genomes Project and projects focused on data
aggregation, such as the Exome Aggregation Consortium
and Genome Aggregation databases, are now freely
available for use in research and diagnostic settings.31,32
The Clinical Genome Resource aims to improve our
understanding of genomic variation through data sharing
and collaboration, starting with aggregating sequence and
structural variants in the National Center for Biotechnol-
ogy Information’s publicly available ClinVar knowledge
base.33–35 There are several other useful databases, such as
the Leiden Open Variation Database (www.lovd.nl/3.0/
home), the Human Gene Mutation Database (www.hgmd.
cf.ac.uk/ac/index.php), and disease-specific databases such
as the Clinical and Functional Translation of CFTR
Mutation Database (cftr2.org) that can be very helpful in
obtaining variant information. All publications addressing
segregation in families and controls must be carefully
reviewed. Functional studies are helpful in determining if
the variant impacts normal function or expression.
However, these studies may be challenging to interpret
because there are no perfect model systems and results
may be contradictory among different analyses. The final
report should include the variant classification and all the
evidence supporting the variant classification, including
references and whether the variant(s) detected fully or
partially explain the patient’s phenotype.29
As the number of sequencing variants grows, additional
evidence may warrant variant reanalysis. For example, the
access to sequence data on more than 60 000 individuals in
the Exome Aggregation Consortium database (exac.
broadinstitute.org) has led many variants of uncertain
significance to be reclassified as benign. To set appropriate
expectations, laboratories may develop policies on the
reanalysis of genetic data.
QUALITY ASSURANCE AND QUALITY CONTROL
General quality assurance and quality control recommen-
dations are stated in the Clinical Laboratory Amendment of
1988, and more specific molecular and sequencing quality
assurance and quality control recommendations have been
articulated by the Clinical Laboratory Standards Institute
(MM9-A2, MM20) and the College of American Patholo-
gists, the American College of Medical Genetics and
Genomics, and the Association for Molecular Patholo-
gy.3,6,22,36
A quality assurance program for NGS testing will assess
preanalytic, analytic, and postanalytic processes used from
enrichment and sequence analysis through reporting. The
program addresses problems that arise in the course of
testing, such as events that can affect the test result or
nonconformance with the laboratory’s own policies and
procedures. Documentation includes both review of the
effectiveness of corrective actions taken and the revision of
policies and procedures intended to prevent recurrence.
Documentation of all testing processes is a critical part
of laboratory quality assurance. All standard operating
protocols of DNA/RNA sample preparation, fragmenta-
tion, library preparation, bar coding (molecular indexing),
sample pooling, and sequence generation are documented
so that each step and subsequent manipulations can be
traced. Metrics and quality control parameters used to
assess run performance are also documented. Commonly
used metrics include the fraction of bases meeting
specified quality and coverage thresholds and average
coverage/base and target region (Table 4; Supplemental
Table 3). The laboratory should define and document
acceptance and rejection criteria for each test step. It is
critical to determine and summarize regions that failed
analysis (eg, because of inadequate coverage) if they are
not covered by orthogonal technologies such as Sanger
sequencing. Assuring sample traceability throughout the
whole analysis workflow is critical so that sample swaps
can be easily detected.
The routine application of a validated bioinformatics
pipeline is accompanied by monitoring of laboratory-
determined quality control metrics. Divergence from ex-
pected quality metrics during the analysis of clinical samples
requires investigation and resolution. These metrics are
assessed per run/sample as well as routinely to detect
trends. An example would be when the bioinformatics
output of NGS data demonstrates an insufficient number of
sequence reads passing an expected or required base quality
score threshold. Deviations may indicate a technical
aberration or process failure occurring during technical
wet bench procedures or during a step in the bioinformatics
pipeline. It is suggested that the clinical laboratory review a
summary of the quality scores, metrics, and total number of
reads to determine overall quality of the run before start of
alignment given the time and other resources required.
Quality control procedures are designed to ensure expected
test performance, detect assay failure, and provide confi-
dence that a reliable result is generated.
Example
For the NGS targeted panel performed at the Children’s
Hospital of Philadelphia, the quality control metrics along
with the criteria used are listed in Table 4. Preanalytic,
analytic, and postanalytic metrics of the wet bench as well as
the bioinformatics pipeline are established, providing
criteria for beginning to end of the NGS workflow. Metrics
are monitored per sample/run and assessed monthly as part
of a continuous quality improvement program.
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IMPLEMENTATION
Before implementation, a validation report must be
written and approved by the laboratory director. This report
should include an introduction to the test; the diseases/
genes being tested; a description of the samples, controls,
and methodology used including bioinformatics; validation
parameters such as precision, specificity, sensitivity, report-
able range, and reference range; and clinical validity and
utility of the test. A standard operating procedure is
composed that includes test indication, intended use, test
principle, specimen handling and storage, reagents and
controls, equipment, the stepwise assay procedure, results
interpretation and report generation, and references. Inte-
gration into the clinical workflow involves training technol-
ogists who will perform the test. Training technologists
comprises not only technical aspects of running the test, but
also disease information to aid in the understanding of a
result and its interpretation. Report templates for negative,
positive, and uncertain results are drafted; however,
customization is often performed and determined by the
classification of the observed genetic variants. All equipment
that is used should be properly installed, inspected, and
maintained continually as long as the test is offered.
Procedures for instrument, operation, and performance
qualification are available and in place. Quality control
and quality assurance measures, including proficiency
testing and archiving of records, reports, and tested
specimens, should be performed. The billing mechanism
and budgetary allocations should also be finalized before the
test is operational. Appropriate regulatory agencies may
need to be notified (and in some cases may require
preapproval) before test implementation. All of these
measures need to be ready before offering the test. It is
important to keep in mind that validation is a continuous
process of monitoring, documentation, and improvement.
This is especially significant in the continually evolving field
of NGS with frequent improvements in technology and
informatics tools. Clinical laboratories must therefore
carefully balance improvements in test performance with
available resources.
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